2 weeks Ago By ABMN Staff
Rhumbline Advisers boosted its stake in shares of Coherus BioSciences, Inc. ( NASDAQ:CHRS – Free Report ) by 19.5% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission.
The fund owned 154,904 shares of the biotechnology company’s stock after acquiring an additional 25,241 shares during the quarter. Rhumbline Advisers’ holdings in Coherus BioSciences were worth $268,000 as of its most recent SEC filing. Several other institutional investors have also recently bought and sold shares of the stock.
Price T Rowe Associates Inc. MD lifted its holdings in Coherus BioSciences by 32.7% during the first quarter.
Price T Rowe Associates Inc. MD now owns 30,851 shares of the biotechnology company’s stock worth $74,000 after acquiring an additional 7,608 shares in the last quarter. China Universal Asset Management Co.
Ltd. lifted its stake in shares of Coherus BioSciences by 66.4% during the 1st quarter.
China Universal Asset Management Co. Ltd. now owns 21,426 shares of the biotechnology company’s stock worth $51,000 after buying an additional 8,546 shares during the last quarter.
Nisa Investment Advisors LLC grew its holdings in Coherus BioSciences by 2,672.8% in the 2nd quarter. Nisa Investment Advisors LLC now owns 20,657 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 19,912 shares in the last quarter.
Bayesian Capital Management LP acquired a new position in shares of Coherus BioSciences during the 1st quarter worth approximately $56,000. Finally, Virtu Financial LLC acquired a new stake in shares of Coherus BioSciences during the 1st quarter worth $94,000. Institutional investors own 72.
82% of the company’s stock. Coherus BioSciences Stock Down 0.9 % Coherus BioSciences stock opened at $1.
05 on Friday. The company has a market capitalization of $120.46 million, a PE ratio of -1.
35 and a beta of 0.66. Coherus BioSciences, Inc.
has a twelve month low of $0.97 and a twelve month high of $4.02.
The firm has a fifty day simple moving average of $1.33 and a two-hundred day simple moving average of $1.75.
Analysts Set New Price Targets CHRS has been the topic of several research analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Coherus BioSciences in a research note on Monday, September 16th.
UBS Group downgraded shares of Coherus BioSciences from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $4.00 to $1.50 in a research report on Friday, August 16th.
StockNews.com downgraded shares of Coherus BioSciences from a “buy” rating to a “hold” rating in a research report on Friday, September 6th. Finally, Robert W.
Baird lowered their price objective on shares of Coherus BioSciences from $9.00 to $8.00 and set an “outperform” rating on the stock in a report on Monday, July 1st.
Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $6.92.
Read Our Latest Stock Analysis on Coherus BioSciences About Coherus BioSciences ( Free Report ) Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. Further Reading Want to see what other hedge funds are holding CHRS? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Coherus BioSciences, Inc. ( NASDAQ:CHRS – Free Report ). Receive News & Ratings for Coherus BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences and related companies with MarketBeat.
com's FREE daily email newsletter ..
